|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 28, 2002; DOI 10.1182/blood-2001-11-0032.
HEMATOPOIESIS
From the Laboratory of Molecular and Cellular
Pathology, and the Laboratory of Environmental Biology, Hokkaido
University School of Medicine, Sapporo, Japan; and CREST, Japan Science
and Technology Corporation.
The CDM (ced-5 of Caenorhabditis
elegans, DOCK180
[downstream of Crk
with molecular weight of 180 kDa] of humans, and
myoblast city of Drosophila
melanogaster) family of proteins has been shown to play a
pivotal role in the integrin-mediated signaling pathway under the
regulation of an adaptor molecule
c-CT10-related kinase II (c-Crk-II) in adherent cells. Recently, hematopoietic
cell-specific CDM protein DOCK2 has been shown to be indispensable for
lymphocyte migration. However, the regulatory mechanism for
DOCK2 is still unknown because DOCK2 lacks a c-Crk-II binding
consensus motif. In this study, we demonstrated that DOCK2 bound to
CrkL, which is present exclusively in hematopoietic cells both
in vivo and in vitro, and we also found that 2 separate regions of
DOCK2 contributed to its binding to Src homology 3 (SH3) domain of CrkL. Colocalization of DOCK2 with Crk-like
(CrkL) and F-actin was shown by immunocytochemical analysis
with the use of Jurkat cells. We also found that CrkL-induced activation of small guanine triphosphatase (GTPase)
Rac1 was significantly inhibited by the DOCK2-dCS mutant in 293T cells.
Furthermore, the association of DOCK2 and Vav, the guanine-nucleotide
exchanging factor (GEF) for Rac1, was demonstrated in Jurkat cells.
Finally, the stable expression of DOCK2-dCS mutant in Jurkat cells was shown to reduce cell attachment. These data suggest the presence of a
novel protein complex of CrkL, DOCK2, and Vav to regulate Rac1 in
leukemia cell lines.
(Blood. 2002;100:3968-3974) The CDM family of proteins is a newly emerging
class of molecules that includes ced-5 of
Caenorhabditis elegans,1
DOCK180 (downstream of
Crk with molecular weight of 180
kDa) of humans,2 and myoblast city of
Drosophila melanogaster,3 and has
been shown to play a pivotal role in the integrin signaling pathway in
the nonhematopoietic lineages of cells. The prototype of the CDM
protein, DOCK180, was isolated as one of the effector molecules of the
signaling adaptor protein
c-CT10-related kinase
II (c-Crk-II),2 and has been shown to regulate
cytoskeletal movement through small guanine triphosphatase
(GTPase) Rac, leading to various cellular responses,
such as phagocytosis, cell migration, and cytoplasmic spreading.4-6 As DOCK180 was not present in hematopoietic
cells,2 the role of CDM proteins in hematopoietic cells
was still under investigation.
DOCK2, found exclusively in hematopoietic cells, belongs to
the CDM family of proteins, and was identified as a homolog of DOCK180
with the use of a cDNA library of the leukemia cell
line.7,8 DOCK2 has been reported to activate
Rac,8 and recently, analysis of DOCK2 knockout mice
clearly demonstrated that DOCK2 plays an essential role in
lymphocyte migration toward chemokines.9 However, the
regulatory mechanism of DOCK2 was still unknown because DOCK2
lacks a binding consensus sequence for the Src homology 3 (SH3)
domain of c-Crk-II.8
Crk-like (CrkL), which is composed of an SH2 domain and two SH3
domains, was isolated as a homolog of c-Crk-II, and its
expression was reported to be dominant in hematopoietic
cells.10,11 CrkL has been shown to be tyrosine
phosphorylated in leukemia cell lines and, in association with
Crk SH3 domain binding GEF (C3G), c-Abl, and DOCK180, is involved in cell adhesion and
migration.12-14 However, a hematopoietic cell-specific
role for CrkL has not yet been established.
The Rho family of small GTPases, including Rho, Rac, and Cdc42
subfamilies, has been shown to regulate the reorganization of the actin
cytoskeleton.15-18 The guanine-nucleotide exchanging factors (GEFs) of the Rho family of proteins share 2 conserved regions,
the Dbl homology (DH) domain19 and the pleckstrin homology (PH) domain.20 The expression of Vav, which is one of the
GEFs for Rac, was observed exclusively in hematopoietic
cells,21 and has been shown to mediate the integrin
signaling pathway by its association with tyrosine kinase
Syk.22,23
In this study, to analyze the role of the CDM family of
proteins in hematopoietic cells, we examined the regulatory mechanism of DOCK2 and found a novel protein complex of CrkL, DOCK2, and Vav,
which leads to the regulation of Rac1 activity and cell adhesion.
Plasmids
Antibodies, reagent, and cells
The 293T human embryonal kidney cells with simian virus40 (SV40) large T antigen were maintained in Dulbecco modified minimum essential medium (DMEM) containing 10% fetal bovine serum (FBS). Jurkat and MOLT4 human T cells, Raji human B cells, and K562 human myeloblast cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% FBS. For establishment of Jurkat cell lines stably expressing DOCK2 and its mutants, cells were transfected with either pCXN2-Flag-DOCK2 wild type (WT) or pCXN2-Flag-DOCK2-dCS by electroporation and selected by 400 µg/mL neomycin for 3 weeks. Several independent colonies were isolated, and protein expression levels were examined by immunoblotting by means of anti-Flag Ab. For establishment of K562 cell lines stably expressing DOCK2, cells were cotransfected with pBabe-Puro and either pCXN2-Flag-DOCK2 WT or pCXN2-Flag-DOCK2-dCS by electroporation and selected by 1 µg/mL puromycin for 1 week. Preparation of human platelets For this study, approval was obtained from the Institutional Review Board of Hokkaido University School of Medicine, and informed consent was provided according to the Declaration of Helsinki. Blood from healthy volunteers was drawn by venipuncture, after informed consent was obtained, and placed into 1:10 volume of 3.8% (wt/vol) trisodium citrate and gently mixed. Platelet-rich plasma (PRP) was prepared by centrifugation of whole blood at 200g for 20 minutes. PRP was aspirated and incubated with 2 µM aspirin for 30 minutes at room temperature. After the addition of prostaglandin E1 at a final concentration of 1 µM, the PRP was spun at 800g to form a soft platelet pellet. The pellet was suspended in 1 mL modified Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-Tyrode buffer containing 129 mM NaCl, 8.9 mM NaHCO3, 0.8 mM KH2PO4, 0.8 mM MgCl2, 5.6 mM dextrose, and 10 mM Hepes (pH 7.4) supplement with apyrase 0.6 U/mL, and washed twice. Platelets (3 × 108 cells per milliliter) were suspended for experiments in modified Hepes-Tyrode buffer supplemented with apyrase (0.6 U/mL) and RGDS peptide (200 µg/mL).Immunoprecipitation and pull-down assay using GST fusion protein Cells were washed with phosphate-buffered saline (PBS) and lysed by Lysis buffer containing 1% Triton-X 100, 10 mM Tris-HCl (pH 7.4), 5 mM EDTA (ethylenediaminetetraacetic acid), 150 mM NaCl, 0.5 mM Na3VO4, 10 mM NaF, 1 µg/mL aprotinin, and 1 mM phenylmethylsulfonyl fluoride (PMSF) and centrifuged at 12 000 rpm at 4°C for 15 minutes. The supernatant was incubated with primary Abs such as anti-CrkL Ab and anti-DOCK2 Ab for 1 hour, and then with a mixture of Protein A-Sepharose 4A and Protein G-Sepharose 4A and anti-CrkL Ab at 4°C for 1 hour with rotation. After washing, the immunocomplexes were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and analyzed by immunoblotting with anti-CrkL, anti-Vav, and anti-DOCK2 Abs.Pull-down assay using glutathione S-transferase (GST) fusion proteins was performed as described.26,27 Briefly, GST fusion proteins were isolated from bacterial lysates by means of glutathione Sepharose beads (Amersham Pharmacia Biotech). After washing with lysis buffer, the beads were incubated with lysates of either cell lines or platelets for 1 hour. Proteins bound to GST fusion proteins were separated by SDS-PAGE, and analyzed by immunoblotting with anti-DOCK2 and anti-GST Abs. Pull-down assay for active form of Rac1 The detection of GTP-bound Rac1 was performed as described previously.28,29 The 293T cells were transfected with expression plasmids with the use of FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) and incubated for 24 hours. For Jurkat and K562 cells, plasmids were transfected by electroporation, and drug-selected cells were used. Cells were lysed with lysis buffer composed of 1% Nonidet P-40, 25 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM MgCl2, 1 µg/mL aprotinin, and 1 mM PMSF. Lysates were centrifuged at 12 000 rpm at 4°C for 1 minute. The supernatant was incubated with 10 µg purified GST-PAK2-RBD and glutathione-Sepharose 4B beads. The beads were washed 3 times with lysis buffer. The precipitates were analyzed by immunoblotting with anti-Flag M2 Ab, and positive signals were visualized by ECL chemiluminescence reaction (Amersham Pharmacia Biotech), and quantified with the use of LAS-1000 plus image analyzer (Fuji Film, Tokyo, Japan).Immunostaining Jurkat cells were transfected with expression plasmids with the use of X-tremeGene Q2 transfection reagent (Roche Diagnostics), and after 24 hours, the cells were plated on fibronectin-coated chamber slides and incubated for 24 hours. Thereafter, cells were fixed with 4% paraformaldehyde in PBS with 0.33 M sucrose at room temperature for 15 minutes, permeabilized with 0.2% Triton X-100 in PBS for 5 minutes, preincubated with 0.1% goat serum in PBS for 10 minutes, and incubated with indicated antibodies or Alexa-594-conjugated phalloidin for 1 hour. For those cases using anti-Flag and anti-CrkL Ab stain, cells were further incubated with antimouse immunoglobulin Ab conjugated with Alexa 488 or Alexa 594, and antirabbit immunoglobulin Ab with Alexa 488. The cells were observed by confocal laser scanning microscopy (Olympus, FV300, Tokyo, Japan).Assessment of cell attachment Jurkat cells were plated on collage type I-coated dishes, incubated at 37°C for 20 minutes, and fixed with 4% paraformaldehyde for 10 minutes at room temperature. Morphology of attached cells was observed by phase contrast microscopy (Olympus).
Association of CrkL with DOCK2 Because the expression of both CrkL and DOCK2 was observed exclusively in hematopoietic cells, we hypothesized that CrkL could be associated with DOCK2 as the analogy of the binding of c-Crk-II and DOCK180 found in nonhematopoietic lineages of cell lines. By pull-down assay, we found that the GST-fusion form of the N-terminal SH3 domain of CrkL could precipitate endogenous DOCK2 in human normal platelets (Figure 1A). We could also observe that DOCK2 was precipitated with GST-CrkL-SH3 in human T-cell lines Jurkat and MOLT4. In this assay, DOCK2 could not be precipitated in human B-cell line Raji or myeloblast cell line K562 (Figure 1B). Among several SH3 domains, including those of Grb2, the p85 subunit of phosphatidyl inositol 3 kinase (PI-3K), v-Src, c-Abl, and mixed lineage kinase 3 (MLK3), we confirmed that none of them bound to DOCK2 (Figure 1C). We also observed that the GST fusion form of the SH3 domain of c-Crk-II precipitated DOCK2, and that introducing point mutation into the essential part of the SH3 domain of c-Crk-II, designated CrkIISH3W169L, failed to maintain the binding to DOCK2 (Figure 1C, lane 5). The full-length form of the wild-type CrkL provided weak signals of DOCK2, whereas the wild-type c-Crk-II did not (Figure 1C).
To confirm the binding of CrkL and DOCK2, the expression plasmids
for CrkL and DOCK2 were transiently transfected in 293T cells, and
immunoprecipitation analysis was performed. Anti-CrkL Ab could
precipitate DOCK2 (Figure 2A), anti-DOCK2
Ab was also found to precipitate CrkL (data not shown). In this
transient protein expression system, we could not find any
coprecipitation of c-Crk-II with DOCK2 (Figure 2B). Furthermore, we
analyzed the binding of endogenous DOCK2 to CrkL in Jurkat, MOLT4, and
Raji cells and found that anti-CrkL Ab and anti-DOCK2 Ab could
precipitate DOCK2 and CrkL, respectively (Figure 2D). Stimulation of
Jurkat cells by collagen type I or poly-L-lysine did not
alter their binding (Figure 2C). We could not find any binding of DOCK2
to c-Crk-II regardless of the stimulation (Figure 2C).
Among the representative GEFs for Rac, the expression of Vav is observed exclusively in hematopoietic cells; we thus examined whether Vav was involved in DOCK2-dependent activation of Rac. In Jurkat cells, Vav was found to be coprecipitated with DOCK2 (Figure 2C). Analysis of the CrkL-binding region of DOCK2 To determine the CrkL-binding regions of DOCK2, we generated truncated mutants of DOCK2 (Figure 3A) and transiently transfected them into 293T cells with the CrkL expression plasmid. As shown in Figure 3B, anti-CrkL antibody precipitated both the dCS mutant composed of 515 amino acids (aa 1-515) of the N-terminus region of DOCK2 (DOCK2-dCS) and the dBE mutant with 538 amino acids (aa 939-1476) (DOCK2-dBE). The CT mutant, which includes a proline-rich region, was not coprecipitated with CrkL. We did not obtain satisfactory expression levels of mutants of INT1 or INT2 (data not shown).
Activation of Rac1 by CrkL and DOCK2 in 293T cells To examine the mechanism of the DOCK2-induced Rac1 activation, we employed a pull-down assay using PAK2-RBD (Rac-binding domain) to measure the amount of the active form of Rac1. First we established the Jurkat and K562 cell lines stably expressing DOCK2, and examined the levels of GTP form of endogenous Rac1. In spite of a polyclonal state, the levels of GTP-Rac1 in the cells stably expressing DOCK2 were elevated about 2-fold compared with vector-control cells in both cell lines (Figure 4A). In 293T cells, we found that CrkL activated Rac1 2- to 3-fold over the vector control, and confirmed significant activation of Rac1 by DOCK2, similar to the DOCK180 as previously reported8 (Figure 4B). We also confirmed that Vav activated Rac1 2- to 3-fold over the control in 293T cells (Figure 4B).
To determine the region of DOCK2 responsible for the activation of Rac1, the truncated mutants of DOCK2 were cotransfected with Rac1 into 293T cells and subjected to pull-down assay. The DOCK2 dN mutant induced a 2-fold activation of Rac1, while the DOCK2-dBE did not activate Rac1. The levels of activated Rac1 were below the basal level of using vector alone when we introduced DOCK2-dCS (Figure 4C). Because DOCK2-dCS seemed to decrease the levels of the active form of Rac1, we examined whether DOCK2-dCS functions as a dominant-negative molecule against Rac1 activation. In the pull-down assay, dCS suppressed the CrkL-induced Rac1 activation (Figure 4D). As DOCK2 does not contain a homologous region as GEF for Rac1, we examined the possible interaction of GEF with DOCK2, and found that Vav was coprecipitated with DOCK2 in Jurkat cells (Figure 2C). The pull-down assay for Rac1 showed that Vav was found to activate Rac1 (Figure 4B), and this was suppressed by DOCK2-dCS (Figure 4D). Colocalization of DOCK2 with CrkL and F-actin in Jurkat cells To confirm the association of CrkL and DOCK in hematopoietic cells, the subcellular localization of these 2 proteins was analyzed by immunofluorescent staining. As we found by immunoprecipitation analysis, DOCK2 was colocalized with CrkL to the cell membrane of Jurkat cells that were transiently transfected with the expression vectors of CrkL and DOCK2 (Figure 5A). Furthermore, we observed that the colocalization of DOCK2 and F-actin appears in the cortical ring of Jurkat cells (Figure 5B).
Suppression of cell attachment in Jurkat cells by stable expression of DOCK2-dCS To examine the functional interaction of CrkL and DOCK2 in hematopoietic cells, we established Jurkat cell lines expressing the DOCK2-WT and its mutant, DOCK2-dCS. The expressed proteins were analyzed by immunoblotting using anti-Flag tag Ab (Figure 6A), and we confirmed that DOCK2-WT induced Rac1 activation and that the dCS mutant suppressed this activation (Figure 6B). Correlating this with the suppression of Rac1 activity by the dCS mutant, Jurkat cells expressing dCS did not exhibit significant attachment of the cells onto collagen-coated dishes (Figure 6C). However, Jurkat-dCS cells attached onto poly-L-lysine-coated dishes in a manner similar to parental cells or those with DOCK2-WT (Figure 6C). We did not observe a significant difference in cell adhesion of Jurkat cells with DOCK2-WT, when compared with their parental Jurkat cells, even on collagen-coated dishes (Figure 6C).
Recently, one of the roles of the hematopoietic cell-specific CDM protein DOCK2 has been demonstrated through the analysis of DOCK2 knockout mice in which DOCK2 was shown to play an essential role for cell migration of both T and B lymphocytes toward chemokines.9 Although the study of DOCK2 knockout mice clearly demonstrated the novel function of DOCK2, the regulatory mechanism of DOCK2 remains unknown because DOCK2 lacks the SH3 domain-binding consensus motif of c-Crk-II, such as PPXLPXK.30 Considering that CrkL shares high sequence homology with c-Crk-II and that its expression is dominant in hematopoietic cells, CrkL seemed to function as the upstream regulatory protein of DOCK2, and we have proven the association of CrkL and DOCK2 both in vivo and in vitro. The colocalization of CrkL and DOCK2 was observed by immunocytochemical analysis. Furthermore, the suppression of CrkL-induced Rac1 activation by DOCK2-dCS mutant also suggested the association of CrkL and DOCK2. As c-Crk-II did not associate with DOCK2, the complex formation of CrkL and DOCK2 suggests the differential binding specificity of SH3 domains of highly homologous proteins such as CrkL and c-Crk-II. Although we did not detect the binding between c-Crk-II and DOCK2, the SH3 domain of c-Crk-II alone, such as GST-c-Crk-II-SH3(N), was unexpectedly found to precipitate DOCK2 in Jurkat cell lysates. The steric hindrance of the full-length form of c-Crk-II masking its SH3(N) domain may explain the differential binding ability of c-Crk-II and its deletion mutant c-Crk-II-SH3(N). As the SH2 domain of CrkL has been reported to bind to CD34 while c-Crk-II has not,31 CrkL and c-Crk-II may have a unique SH2 domain-binding upstream regulator and an SH3 domain-binding downstream effector. The analysis with DOCK2 mutants showed that CrkL bound to 2 separate regions of DOCK2, such as dCS and dBE. However, these regions do not contain any proline-rich sequence which would possibly bind to SH3 domains. The CT mutant contains proline-rich sequences but did not bind to CrkL. Therefore, a possible proline-independent fashion of SH3 binding seems to be involved. Recently, the SH3 domain of another adaptor molecule, Grb2, has been shown to interact with the SH3 domain of Vav in a proline-independent manner. Three-dimensional structural analysis revealed that the SH3 domain of Vav formed a structure mimicking the binding surface of the proline-rich consensus motif for association with the Grb2 SH3 domain.32 One of these CrkL-binding regions of DOCK2, dCS region, has an SH3 domain; the novel interaction found in the complex of the SH3 domain of Grb2 and Vav may be involved in the binding between CrkL and DOCK2. As DOCK2 does not contain a homologous region for GEF for small G
proteins, we hypothesized that some GEFs may form a complex with DOCK2.
Abundant expression of Vav in hematopoietic cells prompted us to
examine whether DOCK2 binds to Vav, and we found the complex formation
in Jurkat cells. However, the association of DOCK2 and Vav may be
indirect because we did not observe direct interaction of overexpressed
forms of these 2 proteins in 293T cells (data not shown). As DOCK2
activated Rac1 at a significantly higher level than did Vav, DOCK2 is
considered to use other GEFs, in addition to Vav, for Rac1. In
fact, introduction of the dominant-negative form of Vav (Vav For further analysis of the binding of CrkL and DOCK2, we established a Jurkat cell line expressing the dCS mutant of DOCK2. In cell attachment assays, this Jurkat-DOCK2-dCS cell line reduced its binding ability onto collagen-coated dishes. As CrkL has been shown to regulate cell adhesion through C3G, which is GEF for Rap1 and R-Ras,12,14,33,34 the DOCK2 dCS mutant may affect the interaction of CrkL and C3G, in addition to that of CrkL and DOCK2 itself. The overexpression of DOCK2-dCS mutant theoretically dissociates both CrkL-DOCK2 and CrkL-C3G complexes, because DOCK2 and C3G share the same binding site, the CrkL-SH3 domain. Therefore, we conclude that the overexpression of DOCK2-dCS interacts with wild-type CrkL in vivo with a certain affinity resulting in the alteration of biological phenotype shown, for example, in cell attachment onto collagen-coated dishes. Thus, this functional interference of the binding of CrkL and its effectors by dCS firmly demonstrated the binding of CrkL and DOCK2 in Jurkat cells. In this study, we demonstrated the association between CrkL and DOCK2 and its regulation of Rac1 in leukemia cell lines. Considering the recent report describing that the lymphocytes of DOCK2 knockout mice decreased chemotaxis,9 the complex of CrkL and DOCK2 may regulate cell motility through Rac, in addition to regulating cell attachment by the CrkL/C3G/Rap1-mediated signaling mechanism. It is worth describing that DOCK2-overexpressed Jurkat cells did not exhibit enhanced cell migration by chemokines in a transwell assay, and the current interpretation is that migration ability is maxmum in the wild-type cells (data not shown). We also tried to demonstrate DOCK2 Rac1 activation in primary B or T lymphocytes and measured the alteration of chemotactic ability to ensure the physiological relevance of the CrkL/DOCK2 signaling pathway. However, lower transfection efficiency hindered the analysis, and future experiments should use an improved transfection technique such as the adenovirus system. As Rac has been reported to induce actin polymerization by T-cell antigen receptor (TCR) stimulation,35 DOCK2 may play a role in the TCR-mediated signaling pathway through Rac activation, leading to various cellular responses. In fact, DOCK2 was found to activate the IL-2 promotor, and we are currently analyzing that mechanism (data not shown). As CrkL has been shown to enhance cell migration by integrin stimulation36 in leukemia cell line, and as a recent study of double-transgenic mice with CrkL and Brc/Abl demonstrated enhanced leukemogenesis,37 the CrkL/DOCK2 complex may be involved in the fundamental mechanism for leukemogenesis. Furthermore, inhibition of the function of the CrkL-SH3 domain by peptide has been shown to suppress proliferation of primary blast cells from CML patients,38 and the association of CrkL and DOCK2 is thought to be one of the therapeutic targets for leukemia.
We thank Dr Michiyuki Matsuda (Osaka University, Japan) for cDNA of DOCK180 and DOCK2 and its mutants; Dr John Groffen (Children's Hospital of Los Angeles) for CrkL cDNA; Dr Silvio J. Gutkind (National Institutes of Health) for Rac1 cDNA; Junichi Miyazaki (Osaka University, Japan) for pCXN2 vector; Dr Brian J. Druker (Oregon Health Sciences University) for pGEX-CrkL-SH3(N); Dr J. M. Adams (Institute of Medical Research, Melbourne, Australia) for c-Vav cDNA; and Sumie Oikawa for technical assistance.
Submitted November 26, 2001; accepted May 10, 2002.
Prepublished online as Blood First Edition Paper, June 28, 2002; DOI 10.1182/blood-2001-11-0032.
Supported in part by Grants-in-Aid from The Ministry of Education, Science, Culture, and Sports in Japan; Human Frontier Science Program (A.O.); Mishima Kaiun Memorial Foundation (A.O.); Mitsui Insurance Welfare Foundation (A.O.); and Welfide Medicinal Research Foundation (A.O.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Shinya Tanaka, Laboratory of Molecular & Cellular Pathology, Hokkaido University School of Medicine, N 15, W 7, Kita-ku, Sapporo, 060-8638, Japan; e-mail: sitanaka{at}patho2.med.hokudai.ac.jp.
1. Wu YC, Horvitz HR. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature. 1998;392:501-504[CrossRef][Medline] [Order article via Infotrieve]. 2. Hasegawa H, Kiyokawa E, Tanaka S, et al. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol Cell Biol. 1996;16:1770-1776[Abstract].
3.
Erickson MR, Galletta BJ, Abmayr SM.
Drosophila myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization.
J Cell Biol.
1997;138:589-603
4.
Kiyokawa E, Hashimoto Y, Kobayashi S, Sugimura H, Kurata T, Matsuda M.
Activation of Rac1 by a Crk SH3-binding protein, DOCK180.
Genes Dev.
1998;12:3331-3336 5. Reddien PW, Horvitz HR. CED-2/CrkII and CED-10/Rac control phagocytosis and cell migration in Caenorhabditis elegans. Nat Cell Biol. 2000;2:131-136[CrossRef][Medline] [Order article via Infotrieve]. 6. Albert ML, Kim JI, Birge RB. alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat Cell Biol. 2000;2:899-905[CrossRef][Medline] [Order article via Infotrieve]. 7. Nagase T, Seki N, Ishikawa K, et al. Prediction of the coding sequences of unidentified human genes, VI: the coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain. DNA Res. 1996;3:321-329[Abstract],341-354. 8. Nishihara H, Kobayashi S, Hashimoto Y, et al. Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins. Biochim Biophys Acta. 1999;1452:179-187[Medline] [Order article via Infotrieve]. 9. Fukui Y, Hashimoto O, Sanui T, et al. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature. 2001;412:826-831[CrossRef][Medline] [Order article via Infotrieve]. 10. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8:2469-2474[Medline] [Order article via Infotrieve].
11.
ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J.
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
Blood.
1994;84:1731-1736
12.
Arai A, Nosaka Y, Kohsaka H, Miyasaka N, Miura O.
CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G.
Blood.
1999;93:3713-3722 13. Uemura N, Salgia R, Ewaniuk DS, Little MT, Griffin JD. Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999;18:3343-3353[CrossRef][Medline] [Order article via Infotrieve].
14.
Uemura N, Griffin JD.
The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration.
J Biol Chem.
1999;274:37525-37532 15. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81:53-62[CrossRef][Medline] [Order article via Infotrieve]. 16. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70:401-410[CrossRef][Medline] [Order article via Infotrieve]. 17. Chant J, Stowers L. GTPase cascades choreographing cellular behavior: movement, morphogenesis, and more. Cell. 1995;81:1-4[CrossRef][Medline] [Order article via Infotrieve].
18.
Mackay DJ, Hall A.
Rho GTPases.
J Biol Chem.
1998;273:20685-20688 19. Whitehead IP, Campbell S, Rossman KL, Der CJ. Dbl family proteins. Biochim Biophys Acta. 1997;1332:F1-F23[Medline] [Order article via Infotrieve]. 20. Lemmon MA, Ferguson KM, Schlessinger J. PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell. 1996;85:621-624[CrossRef][Medline] [Order article via Infotrieve]. 21. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 1989;8:2283-2290[Medline] [Order article via Infotrieve].
22.
Teramoto H, Salem P, Robbins KC, Bustelo XR, Gutkind JS.
Tyrosine phosphorylation of the vav proto-oncogene product links FcepsilonRI to the Rac1-JNK pathway.
J Biol Chem.
1997;272:10751-10755
23.
Obergfell A, Judd BA, del Pozo MA, Schwartz MA, Koretzky GA, Shattil SJ.
The molecular adapter SLP-76 relays signals from platelet integrin alphaIIbbeta3 to the actin cytoskeleton.
J Biol Chem.
2001;276:5916-5923
24.
Heaney C, Kolibaba K, Bhat A, et al.
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Blood.
1997;89:297-306
25.
Tanaka S, Hattori S, Kurata T, et al.
Both the SH2 and SH3 domains of human CRK protein are required for neuronal differentiation of PC12 cells.
Mol Cell Biol.
1993;13:4409-4415
26.
Oda A, Miyakawa Y, Druker BJ, et al.
Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
Blood.
1996;88:4304-4313
27.
Oda A, Ochs HD, Lasky LA, et al.
CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk.
Blood.
2001;97:2633-2639
28.
Akasaki T, Koga H, Sumimoto H.
Phosphoinositide 3-kinase-dependent and -independent activation of the small GTPase Rac2 in human neutrophils.
J Biol Chem.
1999;274:18055-18059 29. del Pozo MA, Price LS, Alderson NB, Ren XD, Schwartz MA. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J. 2000;19:2008-2014[CrossRef][Medline] [Order article via Infotrieve].
30.
Matsuda M, Ota S, Tanimura R, et al.
Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins.
J Biol Chem.
1996;271:14468-14472
31.
Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ.
The adapter protein CrkL associates with CD34.
Blood.
2001;97:3768-3775 32. Nishida M, Nagata K, Hachimori Y, et al. Novel recognition mode between Vav and Grb2 SH3 domains. EMBO J. 2001;20:2995-3007[CrossRef][Medline] [Order article via Infotrieve].
33.
Tanaka S, Morishita T, Hashimoto Y, et al.
C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins.
Proc Natl Acad Sci U S A.
1994;91:3443-3447 34. Ohba Y, Ikuta K, Ogura A, et al. Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. EMBO J. 2001;20:3333-3341[CrossRef][Medline] [Order article via Infotrieve].
35.
Arrieumerlou C, Randriamampita C, Bismuth G, Trautmann A.
Rac is involved in early TCR signaling.
J Immunol.
2000;165:3182-3189
36.
Uemura N, Griffin JD.
The adapter protein Crkl links Cbl and C3g after integrin ligation and enhances cell migration.
J Biol Chem.
1999;274:37525-37532
37.
Hemmeryckx B, van Wijk A, Reichert A, et al.
Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
Cancer Res.
2001;61:1398-1405
38.
Kardinal C, Konkol B, Schulz A, et al.
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
FASEB J.
2000;14:1529-1538
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  Q. Shen, J. J. Rahn, J. Zhang, N. Gunasekera, X. Sun, A. R.E. Shaw, M. J. Hendzel, P. Hoffman, A. Bernier, and J. C. Hugh MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1 Mol. Cancer Res., April 1, 2008; 6(4): 555 - 567. [Abstract] [Full Text |
Top
Abstract
Introduction
DOCK2) Ab. Arrowhead
indicates the size of DOCK2. (B) Lysates of Jurkat and MOLT4 were
subjected to pull-down assay by GST (lanes 2 and 5) or GST-CrkL-SH3(N)
(lanes 3 and 6). Arrowhead indicates the size of DOCK2. (C) Analysis of
the binding of DOCK2 and various SH3 domains (indicated at the top) by
pull-down assay in Jurkat cells lysates. The precipitates were analyzed
by immunoblotting by means of anti-DOCK2 Ab (top panel) and anti-GST Ab
(bottom panel). Lane 1, pull-down (
) indicates total cell lysates. In
the bottom panel, asterisks indicate the expected size of each SH3
domain-containing proteins.
DH) did
not suppress DOCK2-induced Rac1 activation (data not shown).